Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib and Weekly Paclitaxel in Advanced NSCLC
NCT01179269Phase 2Withdrawn
- Sponsor
- Loyola University Chicago
- Start
- Mar 2010
- Primary completion
- Oct 2012
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in non-small cell lung cancer (NSCLC), sponsored by Loyola University Chicago. Primary endpoint: Objective Response Rate at 2 years. Planned start Mar 2010; status: withdrawn.
02
Drugs
pazopanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01179269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01179269.